Beurs gesloten -
Nasdaq
22:30:00 02-05-2024
|
Variatie 5 dagen
|
Verschil t.o.v. 1 jan (%)
|
1,1
USD
|
-1,79%
|
|
-5,17%
|
-1,79%
|
Fiscaal tijdperk: december |
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Marktkapitalisatie
1 |
182,7
|
48,96
|
42,52
|
41,94
|
-
|
-
|
Bedrijfswaarde
1 |
-3,524
|
-97,32
|
42,52
|
-153,6
|
-202,3
|
-64,87
|
K/w-verhouding
|
-1,65
x
|
-0,55
x
|
-0,61
x
|
-0,64
x
|
-0,93
x
|
-1,36
x
|
Dividendrendement
|
-
|
-
|
-
|
-
|
-
|
-
|
Marktkapitalisatie/omzet
|
145
x
|
8,55
x
|
5,4
x
|
4,32
x
|
1,77
x
|
0,74
x
|
Bedrijfswaarde/omzet
|
-2,8
x
|
-17
x
|
5,4
x
|
-15,8
x
|
-8,55
x
|
-1,15
x
|
Bedrijfswaarde/EBITDA
|
0,04
x
|
1,23
x
|
-0,65
x
|
1,62
x
|
1,65
x
|
0,48
x
|
Bedrijfswaarde/FCF
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
Price to Book
|
0,73
x
|
0,29
x
|
-
|
0,57
x
|
0,69
x
|
1,34
x
|
Aantal aandelen (in duizenden)
|
37.285
|
37.661
|
37.966
|
38.128
|
-
|
-
|
Referentieprijs
2 |
4,900
|
1,300
|
1,120
|
1,100
|
1,100
|
1,100
|
Datum van publicatie
|
30/03/22
|
29/03/23
|
21/03/24
|
-
|
-
|
-
|
Fiscaal tijdperk: december |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Omzet
1 |
0,215
|
0,231
|
1,26
|
5,729
|
7,876
|
9,702
|
23,65
|
56,34
|
EBITDA
1 |
-
|
-47,15
|
-83,1
|
-79,08
|
-65,12
|
-94,6
|
-122,2
|
-136
|
Bedrijfsresultaat (EBIT)
1 |
-
|
-49,18
|
-92,79
|
-90,32
|
-76,2
|
-88,44
|
-83,82
|
-72,51
|
Operationele Marge
|
-
|
-21.290,91%
|
-7.364,13%
|
-1.576,56%
|
-967,45%
|
-911,54%
|
-354,42%
|
-128,7%
|
Resultaat voor belastingen (EBT)
1 |
-
|
-60,73
|
-98,59
|
-88,1
|
-69,2
|
-80,67
|
-67,48
|
-36,5
|
Nettowinst (verlies)
1 |
-
|
-60,73
|
-98,59
|
-88,1
|
-69,2
|
-80,67
|
-68,28
|
-50,71
|
Nettomarge
|
-
|
-26.289,18%
|
-7.824,68%
|
-1.537,76%
|
-878,58%
|
-831,46%
|
-288,72%
|
-90,01%
|
WPA
2 |
-2,180
|
-
|
-2,970
|
-2,360
|
-1,830
|
-1,728
|
-1,182
|
-0,8067
|
Free Cash Flow
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF-marge
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Kasstroomconversie (ebitda)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Kasstroomconversie (nettowinst)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Dividend per aandeel
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Datum van publicatie
|
10/08/20
|
31/03/21
|
30/03/22
|
29/03/23
|
21/03/24
|
-
|
-
|
-
|
Fiscaal tijdperk: december |
2021 Q3
|
2021 Q4
|
2022 Q1
|
2022 Q2
|
2022 Q3
|
2022 Q4
|
2023 Q1
|
2023 Q2
|
2023 Q3
|
2023 Q4
|
2024 Q1
|
2024 Q2
|
2024 Q3
|
2024 Q4
|
---|
Omzet
1 |
0,752
|
0,508
|
0,813
|
1,393
|
2,112
|
1,411
|
1,826
|
1,433
|
2,528
|
2,089
|
2,251
|
2,158
|
2,724
|
2,569
|
EBITDA
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Bedrijfsresultaat (EBIT)
1 |
-23,53
|
-27,08
|
-23,88
|
-23,06
|
-22,35
|
-21,04
|
-18,42
|
-19,83
|
-18,18
|
-19,77
|
-20,41
|
-21,4
|
-21,55
|
-22,68
|
Operationele Marge
|
-3.128,46%
|
-5.329,72%
|
-2.936,78%
|
-1.655,35%
|
-1.058,05%
|
-1.491,14%
|
-1.008,49%
|
-1.383,95%
|
-719,26%
|
-946,19%
|
-906,75%
|
-991,55%
|
-791,12%
|
-882,82%
|
Resultaat voor belastingen (EBT)
1 |
-23,4
|
-27,16
|
-23,68
|
-22,66
|
-21,76
|
-20
|
-16,98
|
-18,06
|
-16,26
|
-17,9
|
-18,7
|
-19,94
|
-20,4
|
-21,62
|
Nettowinst (verlies)
1 |
-23,4
|
-27,16
|
-23,68
|
-22,66
|
-21,76
|
-20
|
-16,98
|
-18,06
|
-16,26
|
-17,9
|
-18,7
|
-19,94
|
-20,4
|
-21,62
|
Nettomarge
|
-3.111,04%
|
-5.345,87%
|
-2.912,42%
|
-1.626,99%
|
-1.030,26%
|
-1.417,22%
|
-929,9%
|
-1.260,08%
|
-643,08%
|
-857,01%
|
-830,85%
|
-924,02%
|
-749,01%
|
-841,65%
|
WPA
2 |
-0,6300
|
-0,7300
|
-0,6400
|
-0,6100
|
-0,5800
|
-0,5300
|
-0,4500
|
-0,4800
|
-0,4300
|
-0,4700
|
-0,4933
|
-0,4300
|
-0,4200
|
-0,4000
|
Dividend per aandeel
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Datum van publicatie
|
9/11/21
|
30/03/22
|
12/05/22
|
10/08/22
|
10/11/22
|
29/03/23
|
11/05/23
|
7/08/23
|
9/11/23
|
21/03/24
|
-
|
-
|
-
|
-
|
Fiscaal tijdperk: december |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Nettoschuldpositie
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Nettokaspositie
1 |
-
|
12
|
186
|
146
|
-
|
196
|
244
|
107
|
Hefboom (schuld/ebitda)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Free Cash Flow
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
ROE (netto-inkomsten/eigen vermogen)
|
-
|
-
|
-
|
-41,8%
|
-
|
-55,5%
|
-48,2%
|
-64,7%
|
ROA (netto-inkomsten/totale activa)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Totale activa
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Nettoactief per aandeel
2 |
-
|
-
|
6,690
|
4,540
|
-
|
1,940
|
1,600
|
0,8200
|
Cashflow per aandeel
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capex
1 |
-
|
3,26
|
-
|
1,95
|
-
|
0,39
|
0,41
|
0,43
|
Capex/omzet
|
-
|
1.412,12%
|
-
|
34,09%
|
-
|
4,02%
|
1,73%
|
0,76%
|
Datum van publicatie
|
10/08/20
|
31/03/21
|
30/03/22
|
29/03/23
|
21/03/24
|
-
|
-
|
-
|
Laatste slotkoers
1,1
USD Gemiddelde koersdoel
4,45
USD Spread / Gemiddelde doel +304,55% Consensus |
Vaira. 1 jan.
|
Kapi.
|
---|
| -1,79% | 41,94 mln. | | -1,65% | 103 mld. | | +6,75% | 101 mld. | | +6,84% | 23,07 mld. | | -12,60% | 22,23 mld. | | -5,48% | 18,05 mld. | | -39,98% | 17,18 mld. | | -10,17% | 16,94 mld. | | +6,12% | 14,07 mld. | | +35,47% | 12,35 mld. |
Biotherapeutische geneesmiddelen
|